Keeping corporations healthy is good business for Livongo
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
Allogene and the need for a reliable cell source
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
Menarini Silicon Biosystems banks on cells for its liquid biopsy
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
With new unicorn status, CMR Surgical sets profitability target
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
Nuvaira hopes to go with the flow in COPD
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
Digital therapeutics have potential but commercial success unproven
Software can be a medical device. Can it also be a drug?
Ablative Solutions has a fight on its hands in renal denervation
Alcohol kills – and in this case, that could be a good thing.
Vizai hopes Medtronic deal will boost sales of its tech – and vice versa
Medtronic decides that Solitaire is best played with a partner.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.